BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 19155235)

  • 1. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Cauli A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Ann Rheum Dis; 2010 Jan; 69(1):61-4. PubMed ID: 19155235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G; Tozman E; Nahar N; Metz D
    Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
    Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH;
    Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.
    Tamirou F; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Fiehn C; Ayala Guttierez Mdel M; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R; Houssiau FA;
    Ann Rheum Dis; 2016 Mar; 75(3):526-31. PubMed ID: 25757867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.
    Fujinaga S; Kaneko K; Ohtomo Y; Murakami H; Takada M; Akashi S; Hira M; Yamashiro Y
    Pediatr Nephrol; 2005 Oct; 20(10):1500-3. PubMed ID: 16021476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
    Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
    Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
    Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.
    Chan TM; Tse KC; Tang CS; Lai KN; Li FK
    Lupus; 2005; 14(4):265-72. PubMed ID: 15864912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive therapy in lupus nephritis.
    D'Cruz D; Cuadrado MJ; Mujic F; Tungekar MF; Taub N; Lloyd M; Khamashta MA; Hughes GR
    Clin Exp Rheumatol; 1997; 15(3):275-82. PubMed ID: 9177922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of proliferative lupus nephritis: a changing landscape.
    Adu D
    Kidney Int; 2006 Aug; 70(4):616-8. PubMed ID: 16900218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome.
    Benseler SM; Bargman JM; Feldman BM; Tyrrell PN; Harvey E; Hebert D; Silverman ED
    Rheumatology (Oxford); 2009 Feb; 48(2):176-82. PubMed ID: 19141574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone.
    Chan TM; Li FK; Wong RW; Wong KL; Chan KW; Cheng IK
    Nephron; 1995; 71(3):321-7. PubMed ID: 8569982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.